Our computational assessment highlights low but increasing COA adoption in neuro-oncology trials, mirroring broader oncology trends and reflecting a cumulative impact of regulatory and advocacy efforts. Priority areas for improvement include early-phase trials, FDA-approved interventions, and treatment-focused studies. Our findings emphasize the need for COA-specific reporting improvements and greater standardization in neuro-oncology research.